Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

AC Immune (ACIU) EBIT (2016 - 2026)

AC Immune has reported EBIT over the past 11 years, most recently at -$18.9 million for Q1 2026.

  • Quarterly EBIT rose 12.35% to -$18.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$80.5 million through Mar 2026, down 39.83% year-over-year, with the annual reading at -$86.7 million for FY2025, 45.05% down from the prior year.
  • EBIT was -$18.9 million for Q1 2026 at AC Immune, down from -$18.0 million in the prior quarter.
  • Over five years, EBIT peaked at $8.4 million in Q3 2024 and troughed at -$23.4 million in Q2 2025.
  • The 5-year median for EBIT is -$19.4 million (2022), against an average of -$17.3 million.
  • The largest YoY upside for EBIT was 147.92% in 2024 against a maximum downside of 432.39% in 2024.
  • A 5-year view of EBIT shows it stood at -$19.4 million in 2022, then surged by 79.43% to -$4.0 million in 2023, then tumbled by 432.39% to -$21.3 million in 2024, then increased by 15.26% to -$18.0 million in 2025, then fell by 4.86% to -$18.9 million in 2026.
  • Per Business Quant, the three most recent readings for ACIU's EBIT are -$18.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$20.2 million (Q3 2025).